Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
000-30929
(Commission
File Number)
|
13-4087132
(IRS
Employer Identification No.)
|
£ |
Written
communications pursuant to Rule 425 under the Securities
Act.
|
£ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act.
|
£ |
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
|
£ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
|
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment
of Certain
Officers; Compensatory Arrangements of Certain
Officers.
|
Item 9.01. |
Financial
Statements and Exhibits.
|
(d) |
Exhibits
|
Exhibit
|
|
Number
|
Description
|
99.1
|
Keryx
Biopharmaceuticals, Inc. 2007 Incentive Plan (incorporated herein
by
reference from Annex D of the Company’s Definitive Proxy Statement on
Schedule 14A (File No. 000-30929) filed with the Securities and Exchange
Commission on April 30, 2007).
|
Keryx
Biopharmaceuticals, Inc.
(Registrant)
|
||
|
|
|
Date: June 25, 2007 | ||
By: | /s/ Beth F. Levine | |
Beth F. Levine |
||
General Counsel and Chief Compliance Officer |